nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—ADRB1—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.0611	0.0634	CbGpPWpGaD
Formoterol—ADRB2—Adrenoceptors—ADRA2C—attention deficit hyperactivity disorder	0.0598	0.062	CbGpPWpGaD
Formoterol—Dobutamine—COMT—attention deficit hyperactivity disorder	0.0362	1	CrCbGaD
Formoterol—ADRB1—Adrenoceptors—ADRA2A—attention deficit hyperactivity disorder	0.0321	0.0333	CbGpPWpGaD
Formoterol—ADRB2—Adrenoceptors—ADRA2A—attention deficit hyperactivity disorder	0.0314	0.0326	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.0216	0.0224	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0212	0.022	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.0211	0.0219	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0207	0.0215	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0182	0.0189	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0178	0.0185	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0178	0.0184	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0174	0.0181	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0128	0.0133	CbGpPWpGaD
Formoterol—CYP2A6—Fluoropyrimidine Activity—DPYD—attention deficit hyperactivity disorder	0.0128	0.0133	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0126	0.013	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0123	0.0128	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0121	0.0125	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0119	0.0124	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0117	0.0121	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0116	0.012	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0114	0.0118	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0113	0.0117	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0112	0.0116	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0111	0.0115	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.011	0.0114	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0108	0.0112	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0106	0.0109	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0104	0.0108	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0102	0.0106	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.01	0.0104	CbGpPWpGaD
Formoterol—ADRB1—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00995	0.0103	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.00981	0.0102	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.00971	0.0101	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00955	0.0099	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0095	0.00986	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00943	0.00978	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.00934	0.00969	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.00922	0.00957	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00878	0.00911	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.00859	0.00891	CbGpPWpGaD
Formoterol—ADRB1—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00734	0.00762	CbGpPWpGaD
Formoterol—ADRB1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00732	0.00759	CbGpPWpGaD
Formoterol—ADRB2—G alpha (s) signalling events—DRD5—attention deficit hyperactivity disorder	0.00718	0.00745	CbGpPWpGaD
Formoterol—ADRB2—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00716	0.00743	CbGpPWpGaD
Formoterol—ADRB1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00615	0.00638	CbGpPWpGaD
Formoterol—ADRB2—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00602	0.00624	CbGpPWpGaD
Formoterol—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0053	0.0055	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.00502	0.00521	CbGpPWpGaD
Formoterol—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00488	0.00506	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00487	0.00506	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00417	0.00433	CbGpPWpGaD
Formoterol—ADRB1—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00414	0.00429	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00409	0.00424	CbGpPWpGaD
Formoterol—ADRB1—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00409	0.00424	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00408	0.00423	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00406	0.00421	CbGpPWpGaD
Formoterol—ADRB2—G alpha (s) signalling events—DRD1—attention deficit hyperactivity disorder	0.00405	0.0042	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.004	0.00415	CbGpPWpGaD
Formoterol—ADRB2—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.004	0.00415	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00397	0.00412	CbGpPWpGaD
Formoterol—CYP2A6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00394	0.00409	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00357	0.00371	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.0035	0.00363	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.0035	0.00363	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00343	0.00355	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00318	0.0033	CbGpPWpGaD
Formoterol—CYP2A6—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00317	0.00329	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00283	0.00294	CbGpPWpGaD
Formoterol—CYP2A6—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00283	0.00293	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00277	0.00288	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00272	0.00282	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00267	0.00277	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00266	0.00276	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00261	0.00271	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00248	0.00257	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00243	0.00252	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00242	0.00251	CbGpPWpGaD
Formoterol—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.0024	0.00249	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00237	0.00246	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.0023	0.00239	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00229	0.00238	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00225	0.00234	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00224	0.00233	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00223	0.00231	CbGpPWpGaD
Formoterol—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00221	0.00229	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00219	0.00227	CbGpPWpGaD
Formoterol—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00219	0.00227	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00218	0.00226	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00216	0.00225	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00214	0.00222	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00212	0.0022	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00212	0.0022	CbGpPWpGaD
Formoterol—CYP2A6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00211	0.00219	CbGpPWpGaD
Formoterol—CYP2A6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00209	0.00217	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00208	0.00216	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00208	0.00215	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00204	0.00211	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00202	0.00209	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00197	0.00205	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00197	0.00205	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00193	0.002	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00191	0.00198	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00188	0.00195	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00187	0.00194	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00185	0.00192	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00185	0.00192	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00184	0.00191	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00181	0.00188	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00181	0.00188	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00173	0.00179	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00169	0.00175	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00162	0.00168	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00158	0.00164	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00154	0.0016	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00151	0.00156	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.0015	0.00156	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.0015	0.00156	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00147	0.00153	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00147	0.00152	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00145	0.00151	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00143	0.00148	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00142	0.00148	CbGpPWpGaD
Formoterol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00141	0.00147	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00141	0.00147	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.0014	0.00145	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.0014	0.00145	CbGpPWpGaD
Formoterol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00138	0.00143	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00138	0.00143	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00137	0.00142	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00137	0.00142	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00134	0.00139	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00132	0.00136	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00129	0.00134	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00129	0.00133	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00128	0.00132	CbGpPWpGaD
Formoterol—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00127	0.00132	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00123	0.00128	CbGpPWpGaD
Formoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00121	0.00126	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.0012	0.00125	CbGpPWpGaD
Formoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00118	0.00123	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00118	0.00123	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00117	0.00122	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00117	0.00122	CbGpPWpGaD
Formoterol—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00117	0.00121	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00116	0.00121	CbGpPWpGaD
Formoterol—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00116	0.0012	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00104	0.00108	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00102	0.00106	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00096	0.000996	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000948	0.000984	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000939	0.000975	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.000928	0.000963	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000921	0.000956	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000913	0.000947	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.000901	0.000935	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.000893	0.000927	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000862	0.000894	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000849	0.000881	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00083	0.000861	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000829	0.00086	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000825	0.000856	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000822	0.000853	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000811	0.000841	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000808	0.000839	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000808	0.000838	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000807	0.000837	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.000804	0.000834	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000798	0.000828	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000793	0.000822	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000791	0.00082	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00079	0.00082	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000781	0.00081	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000775	0.000805	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000771	0.0008	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000754	0.000782	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000746	0.000774	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000743	0.000771	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000734	0.000761	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00073	0.000758	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000727	0.000754	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000725	0.000752	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000718	0.000745	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000709	0.000735	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000675	0.0007	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00066	0.000685	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000595	0.000617	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000595	0.000617	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000585	0.000607	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00056	0.000581	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000548	0.000569	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000544	0.000565	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000526	0.000545	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000521	0.00054	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000509	0.000528	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00049	0.000508	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000483	0.000502	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000479	0.000497	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000479	0.000497	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000476	0.000494	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000473	0.000491	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000462	0.00048	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000455	0.000472	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000453	0.00047	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000445	0.000462	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000441	0.000458	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000433	0.00045	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000431	0.000448	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000428	0.000444	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000424	0.00044	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000419	0.000434	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000399	0.000414	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.00039	0.000405	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000363	0.000376	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000363	0.000376	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—COMT—attention deficit hyperactivity disorder	0.00036	0.000374	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000358	0.000371	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000357	0.00037	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000334	0.000346	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000334	0.000346	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000332	0.000344	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000331	0.000343	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000331	0.000343	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000328	0.000341	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000325	0.000338	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000305	0.000317	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000303	0.000314	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00029	0.000301	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000279	0.00029	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000276	0.000286	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000273	0.000283	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000267	0.000277	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000264	0.000274	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000254	0.000263	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000252	0.000261	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	0.00022	0.000228	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000218	0.000226	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000212	0.00022	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	0.000202	0.00021	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000201	0.000208	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.0002	0.000208	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000199	0.000206	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000193	0.0002	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—EP300—attention deficit hyperactivity disorder	0.000155	0.00016	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000148	0.000154	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000145	0.00015	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	9.43e-05	9.78e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	8.67e-05	8.99e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	8.59e-05	8.92e-05	CbGpPWpGaD
